Knight Therapeutics Reports First Quarter 2026 Results
Knight Therapeutics increased its 2026 revenue guidance to $525 million after achieving record quarterly revenues and Adjusted EBITDA for the period ending March 31, 2026
Montreal-based Knight Therapeutics Inc., which trades on the Toronto Stock Exchange under the symbol GUD, released its financial results for the first quarter of 2026 on May 7. The company, a pan-American pharmaceutical firm with operations outside of the United States, reported that the period ending March 31, 2026, yielded record-high quarterly revenues. This performance represents the highest quarterly revenue, Adjusted EBITDA, and Adjusted EBITDA per share achieved by the company since its inception.[1][2]
Following these record-breaking results, Knight Therapeutics has officially raised its financial expectations for the full 2026 fiscal year. The company increased its annual revenue guidance to $525 million, up from the previously projected $510 million. This upward revision reflects the company's strong start to the year as it continues its operations as a specialized pharmaceutical provider in the international market.[1][2]
